Evaluating the 'return on patient engagement initiatives' in medicines research and development
| Autor: | Claudia Hey, Elisa Ferrer, Tjerk Jan Schuitmaker-Warnaar, Teresa Finlay, Gabor Purman, Jacqueline E. W. Broerse, Mathieu Boudes, Virginie Hivert, Paul Robinson, Ana Diaz, Marie Laure Kürzinger, Nick Fahy, Robert A. Kroes, Lidewij Eva Vat |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
SDG 16 - Peace
literature review Decision Making MEDLINE Review Article medicines development metrics 03 medical and health sciences 0302 clinical medicine framework Humans Family 030212 general & internal medicine Patient participation Review Articles lcsh:R5-920 Medical education evaluation research patient engagement lcsh:Public aspects of medicine 030503 health policy & services Clinical study design SDG 16 - Peace Justice and Strong Institutions Public Health Environmental and Occupational Health Health technology lcsh:RA1-1270 patient and public involvement Grey literature Monitoring and evaluation Justice and Strong Institutions 3. Good health Data extraction impact patient participation lcsh:Medicine (General) 0305 other medical science Psychology Qualitative research |
| Zdroj: | Health Expectations Vat, L E, Finlay, T, Schuitmaker-Warnaar, T J, Fahy, N, Robinson, P, Boudes, M, Diaz, A, Ferrer, E, Hivert, V, Purman, G, Kürzinger, M L, Kroes, R A, Hey, C & Broerse, J E W 2019, ' Evaluating the "return on patient engagement initiatives" in medicines research and development : A literature review ', Health Expectations, vol. 23, no. 1, pp. 5-18 . https://doi.org/10.1111/hex.12951 Health Expectations, Vol 23, Iss 1, Pp 5-18 (2020) Health Expectations : An International Journal of Public Participation in Health Care and Health Policy |
| ISSN: | 1369-6513 |
| DOI: | 10.1111/hex.12951 |
| Popis: | Background Showing how engagement adds value for all stakeholders can be an effective motivator for broader implementation of patient engagement. However, it is unclear what methods can best be used to evaluate patient engagement. This paper is focused on ways to evaluate patient engagement at three decision‐making points in the medicines research and development process: research priority setting, clinical trial design and early dialogues with regulators and health technology assessment bodies. Objective Our aim was to review the literature on monitoring and evaluation of patient engagement, with a focus on indicators and methods. Search strategy and inclusion criteria We undertook a scoping literature review using a systematic search, including academic and grey literature with a focus on evaluation approaches or outcomes associated with patient engagement. No date limits were applied other than a cut‐off of publications after July 2018. Data extraction and synthesis Data were extracted from 91 publications, coded and thematically analysed. Main results A total of 18 benefits and 5 costs of patient engagement were identified, mapped with 28 possible indicators for their evaluation. Several quantitative and qualitative methods were found for the evaluation of benefits and costs of patient engagement. Discussion and conclusions Currently available indicators and methods are of some use in measuring impact but are not sufficient to understand the pathway to impact, nor whether interaction between researchers and patients leads to change. We suggest that the impacts of patient engagement can best be determined not by applying single indicators, but a coherent set of measures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text